Subtopic Deep Dive
Biomarkers for CDK4/6 Inhibitor Response
Research Guide
What is Biomarkers for CDK4/6 Inhibitor Response?
Biomarkers for CDK4/6 inhibitor response are molecular indicators, such as cyclin D1 expression, PIK3CA mutations, and circulating tumor DNA dynamics, that predict therapeutic efficacy in HR-positive advanced breast cancer patients.
Research focuses on validating biomarkers like PD 0332991 sensitivity in luminal ER-positive cell lines (Finn et al., 2009, 1378 citations) and PIK3CA mutations influencing response (André et al., 2019, 2360 citations). Studies integrate multi-omics signatures and liquid biopsies for patient stratification. Over 10 key papers from 2009-2023 highlight preclinical and clinical validation.
Why It Matters
Biomarkers enable precision therapy by stratifying patients for CDK4/6 inhibitors like ribociclib, extending progression-free survival in HR-positive advanced breast cancer (Hortobágyi et al., 2016, 1897 citations). They reduce toxicity in non-responders and guide combinations with PI3K inhibitors for PIK3CA-mutated cases (André et al., 2019). In guidelines, biomarkers inform treatment selection per NCCN and ESO-ESMO consensus (Gradishar et al., 2020; Cardoso et al., 2020).
Key Research Challenges
Biomarker Validation in Clinics
Translating preclinical markers like cyclin D1 from cell lines to patient outcomes remains inconsistent (Finn et al., 2009). Clinical trials show variable response prediction with PIK3CA mutations (André et al., 2019). Larger prospective studies are needed for robust validation.
Resistance Mechanism Identification
CDK4/6 inhibitors face acquired resistance via PI3K/AKT/mTOR pathway alterations (Glaviano et al., 2023). Multi-omics data reveal heterogeneous escape routes (Roberts et al., 2012). Dynamic biomarkers like ctDNA tracking are underexplored.
Liquid Biopsy Standardization
Circulating tumor DNA dynamics for response prediction lack standardized protocols across studies. Integration with tissue biomarkers is challenging (Gelbert et al., 2014). Reproducibility issues hinder clinical adoption.
Essential Papers
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin, Jiang-Jie Duan, Xiu-Wu Bian et al. · 2020 · Breast Cancer Research · 2.4K citations
Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Fabrice André, Eva Ciruelos, Gábor Rubovszky et al. · 2019 · New England Journal of Medicine · 2.4K citations
Treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with <i>PIK3CA</i>-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine ther...
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita et al. · 2022 · New England Journal of Medicine · 2.3K citations
In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of...
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus et al. · 2016 · Annals of Oncology · 2.0K citations
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris et al. · 2016 · New England Journal of Medicine · 1.9K citations
Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving r...
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Jame Abraham et al. · 2020 · Journal of the National Comprehensive Cancer Network · 1.6K citations
Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the t...
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Antonino Glaviano, Aaron Song Chuan Foo, Hiu Yan Lam et al. · 2023 · Molecular Cancer · 1.6K citations
Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth...
Reading Guide
Foundational Papers
Start with Finn et al. (2009) for CDK4/6 inhibitor mechanism in breast cancer cell lines, then Gelbert et al. (2014) for preclinical validation of abemaciclib.
Recent Advances
Study André et al. (2019) for PIK3CA biomarkers in advanced breast cancer and Hortobágyi et al. (2016) for ribociclib PFS outcomes.
Core Methods
Cell cycle inhibition assays (PD 0332991), progression-free survival analysis in trials, PI3K/AKT/mTOR pathway profiling, and guideline-based stratification (NCCN, ESO-ESMO).
How PapersFlow Helps You Research Biomarkers for CDK4/6 Inhibitor Response
Discover & Search
Research Agent uses searchPapers and citationGraph to map 250M+ papers, starting from Finn et al. (2009) as the foundational CDK4/6 inhibitor study, revealing 1378 citing works on biomarkers. exaSearch uncovers recent multi-omics signatures; findSimilarPapers links PIK3CA-related papers like André et al. (2019).
Analyze & Verify
Analysis Agent applies readPaperContent to extract biomarker data from Hortobágyi et al. (2016), then verifyResponse with CoVe checks claims against GRADE grading for evidence strength. runPythonAnalysis processes survival data from ribociclib trials using pandas for statistical verification of PFS differences.
Synthesize & Write
Synthesis Agent detects gaps in resistance biomarkers via contradiction flagging across Finn (2009) and Glaviano (2023). Writing Agent uses latexEditText, latexSyncCitations for guideline-compliant reports, and latexCompile for publication-ready manuscripts with exportMermaid for pathway diagrams.
Use Cases
"Analyze survival data from CDK4/6 inhibitor trials for biomarker correlation"
Research Agent → searchPapers (Hortobágyi 2016) → Analysis Agent → readPaperContent → runPythonAnalysis (pandas Kaplan-Meier plots, HR calculations) → statistical output with p-values and confidence intervals.
"Draft a review on PIK3CA biomarkers in CDK4/6 therapy"
Synthesis Agent → gap detection (André 2019 + Finn 2009) → Writing Agent → latexEditText (structure sections) → latexSyncCitations → latexCompile → LaTeX PDF with synced references.
"Find code for CDK4/6 response prediction models"
Research Agent → paperExtractUrls (Gelbert 2014) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow outputs scripts for multi-omics analysis.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ CDK4/6 papers, chaining searchPapers → citationGraph → GRADE grading for biomarker evidence synthesis. DeepScan applies 7-step analysis with CoVe checkpoints to validate PIK3CA claims from André (2019). Theorizer generates hypotheses on ctDNA dynamics from Finn (2009) and recent guidelines.
Frequently Asked Questions
What defines biomarkers for CDK4/6 inhibitor response?
Molecular indicators like cyclin D1 expression and PIK3CA mutations predict response in HR-positive breast cancer (Finn et al., 2009; André et al., 2019).
What are key methods for biomarker discovery?
Preclinical cell line assays (PD 0332991, Finn et al., 2009), clinical trials (ribociclib, Hortobágyi et al., 2016), and PI3K pathway analysis (Glaviano et al., 2023).
What are foundational papers?
Finn et al. (2009, 1378 citations) established CDK4/6 selectivity in ER-positive lines; Gelbert et al. (2014) characterized LY2835219 preclinical activity.
What open problems exist?
Standardizing liquid biopsies, predicting resistance via multi-omics, and prospective validation in diverse populations (Cardoso et al., 2020; Roberts et al., 2012).
Research Advanced Breast Cancer Therapies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Biomarkers for CDK4/6 Inhibitor Response with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Advanced Breast Cancer Therapies Research Guide